The NY-based venture capital fund, ATEM Capital, focuses on investing in BioPharma, MedTech, and Digital Health breakthroughs that prioritize therapeutic areas such as oncology, autoimmune, cardiovascular, neurology diseases, and infections. ATEM Capital has had over ten successful co-investments with leading venture firms in the US and Europe, as well as with corporate venture firms such as Pfizer, Roche, J&JDC, and Novo. The team members have extensive experience in product launches, investment management, and exits of venture-backed companies, having invested over $30 billion overall. Founded in 2020, ATEM Capital prefers to invest in the life science industry, with a focus on immuno-oncology, autoimmune, rare diseases, and neurology.